Preclinical evidence suggests the antitumor synergistic efficacy of CDK4/6 inhibitors, with BRAF/MEK inhibitors and MEK inhibitors, in BRAF and NRAS mutant melanomas, respectively [135,136,137]. The gene discussed is NRAS; the disease is melanoma.